Medical Grand Rounds

*Presented by*

Yale School of Medicine, Department of Internal Medicine,

Section of Hematology and Oncology

Nikolai Podoltsev, MD, PhD

Associate Professor of Internal Medicine (Hematology);

Associate Director of the Hematology/Oncology Fellowship Program

“Polycythemia Vera: Epidemiology, Prognosis, and Real-World Outcomes”

**Date: August 20, 2020 Time: 8:30-9:30am**

**Location:** [**https://zoom.us/j/94896766303?pwd=UWFrcG9GNXMvcWZ3YU4ycUc5VEVSdz09**](https://zoom.us/j/94896766303?pwd=UWFrcG9GNXMvcWZ3YU4ycUc5VEVSdz09)

***There is no corporate support for this activity***

This course will fulfill the licensure requirement set forth by the State of Connecticut

**ACCREDITATION:**

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**TARGET AUDIENCE:**

**Attending physicians, house staff, fellows, medical students, PA’s**

**NEEDS ASSESSMENT:**

Polycythemia vera is a chronic myeloproliferative neoplasm characterized by increased red blood cell mass. Clinicians need to know about the diagnostic criteria, epidemiology, pathogenesis, management options, and outcomes of this blood disorder.

**LEARNING OBJECTIVES:**

1. Know the diagnostic criteria of polycythemia vera, (PV), it’s epidemiology and pathogenesis
2. Learn the approach to patients with erythrocytosis, PV risk stratification and complications
3. Understand current management options including cytoreductive therapies and real-world outcomes

**DESIGNATION STATEMENT**

The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

**FACULTY DISCLOSURES:**

Course Director: Vincent Quagliarello, MD - None

Speaker: Nikolai Podolstev, MD, PhD-

PharmaEssentia; Honorarium; Scientific Advisory Board

CTI BioPharma; Honorarium; Scientific Advisory Board

Bristol-Myers- Squib; Honorarium; Scientific Advisory Board

Celgene; Consulting fee; Consulting

Novartis; Honorarium; Scientific Advisory Board

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.